Q2 25 EPS
$-0.09
BEAT +0.00%
Est. $-0.09
Q2 25 Revenue
$11.4M
MISS 2.79%
Est. $11.7M
vs S&P Since Q2 25
+90.7%
BEATING MARKET
APYX +112.0% vs S&P +21.4%
Market Reaction
Did APYX Beat Earnings? Q2 2025 Results
Apyx Medical delivered a mixed but pivotal second quarter, matching the Wall Street consensus on earnings while falling just short on revenue, as the company's most consequential product launch in years stole the spotlight from the headline numbers. … Read more Apyx Medical delivered a mixed but pivotal second quarter, matching the Wall Street consensus on earnings while falling just short on revenue, as the company's most consequential product launch in years stole the spotlight from the headline numbers. Revenue declined 6.4% year over year to $11.37 million, missing the $11.70 million consensus estimate by 2.79%, with a 28.5% drop in OEM segment sales dragging on total results even as the core Advanced Energy business held relatively steady. The company lost $0.09 per share, in line with estimates, while the net loss narrowed sharply to $3.78 million from $6.56 million a year ago, reflecting aggressive cost discipline that trimmed total operating expenses by $3.40 million. The real story, however, was the FDA clearance and soft launch of the AYON Body Contouring System, which drew stronger-than-expected early surgeon interest and prompted management to raise full-year 2025 revenue guidance to $50.00 million to $52.00 million, up from a prior range of $47.60 million to $49.00 million, with a nationwide rollout planned for September.
Key Takeaways
- • Advanced Energy segment revenue relatively flat year-over-year at $9.7 million
- • Gross margin improved to 62.3% from 61.7% due to favorable product mix shift toward Advanced Energy
- • Operating expenses decreased $3.4 million driven by reductions in salaries, SG&A, R&D, and professional services
- • Net loss narrowed by 42% year-over-year to $3.8 million
- • Adjusted EBITDA loss improved 54% to $2.0 million
APYX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Building on the growing success of Renuvion in the U.S., we recently initiated the soft commercial launch of the AYON following FDA clearance in the second quarter of 2025. Customer interest in AYON quickly exceeded our expectations for this early stage of the rollout, with surgeons selected to be early adopters already installing our system and performing initial procedures. As a result, we have increased our revenue guidance for the full year 2025 to $50.0 million to $52.0 million and look forward to a nationwide launch of AYON in September.”
— Charlie Goodwin, Q2 2025 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |